Country: Canada
Language: English
Source: Health Canada
METOPROLOL TARTRATE
DOMINION PHARMACAL
C07AB02
METOPROLOL
50MG
TABLET
METOPROLOL TARTRATE 50MG
ORAL
300
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0111923002; AHFS:
APPROVED
1997-04-24
PRODUCT MONOGRAPH PR DOM-METOPROLOL-L Metoprolol Tartrate Tablets, USP 25 mg, 50 mg and 100 mg Β-ADRENERGIC RECEPTOR BLOCKING AGENT DOMINION PHARMACAL 6111 Royalmount Ave., Suite 100 Montréal, Canada H4P 2T4 DATE OF REVISION: September 27, 2016 SUBMISSION CONTROL NO: 197897 _Dom-METOPROLOL-L Product Monograph _ _Page 2 of 38_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................. 4 ADVERSE REACTIONS.................................................................................................. 10 DRUG INTERACTIONS .................................................................................................. 13 DOSAGE AND ADMINISTRATION .............................................................................. 17 OVERDOSAGE ................................................................................................................ 19 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 20 STORAGE AND STABILITY .......................................................................................... 24 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 24 PART II: SCIENTIFIC INFORMATION ............................................................................... 25 PHARMACEUTICAL INFORMATION.......................................................................... 25 DETAILED PHARMACOLOGY ..................................................................................... 26 TOXICOLOGY ......................................... Read the complete document